Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dons

Showing results (191-200 of 199) with videos related to

Pageof 20
Sort By:
You have reached the last page of results.This site can display upto 199 results.
JAMA|August 30, 2025
Bivalent RSV Prefusion F Protein-Based Vaccine for Preventing Cardiovascular Hospitalizations in Older Adults: A Prespecified Analysis of the DAN-RSV TrialMats C Højbjerg Lassen, Niklas Dyrby Johansen, Sine H Christensen, et al.
European Journal of Preventive Cardiology|April 30, 2026
Respiratory syncytial virus vaccination and risk of respiratory and cardiorespiratory hospitalization in adults with chronic kidney disease: a prespecified analysis of the DAN-RSV trialLisa Steen Duus, Mats C H Lassen, Niklas D Johansen, et al.
European Journal of Preventive Cardiology|June 18, 2026
Effect of RSV Vaccine in Older Adults with Atrial Fibrillation: A Prespecified Analysis of the DAN-RSV TrialCaroline Espersen, Mats C H Lassen, Niklas Dyrby Johansen, et al.
JAMA Cardiology|August 30, 2025
High-Dose vs Standard-Dose Influenza Vaccine and Cardiovascular Outcomes in Older Adults: A Prespecified Secondary Analysis of the DANFLU-2 Randomized Clinical TrialNiklas Dyrby Johansen, Daniel Modin, Matthew M Loiacono, et al.
European Heart Journal|August 30, 2025
High-dose vs. standard-dose inactivated influenza vaccine and cardiovascular outcomes in persons with or without pre-existing atherosclerotic cardiovascular disease: the DANFLU-2 trialManan Pareek, Niklas Dyrby Johansen, Daniel Modin, et al.
Journal of the American College of Cardiology|November 26, 2025
High-Dose vs Standard-Dose Influenza Vaccine in Chronic Kidney Disease: The DANFLU-2 Trial Subgroup AnalysisKatja Vu Bartholdy, Niklas Dyrby Johansen, Daniel Modin, et al.
The New England Journal of Medicine|September 1, 2025
High-Dose Influenza Vaccine Effectiveness against Hospitalization in Older AdultsNiklas Dyrby Johansen, Daniel Modin, Matthew M Loiacono, et al.
Circulation. Heart Failure|August 30, 2025
High-Dose vs. Standard-Dose Influenza Vaccine in Heart Failure: A Prespecified Analysis of the DANFLU-2 TrialKristoffer Grundtvig Skaarup, Niklas Dyrby Johansen, Daniel Modin, et al.
JAMA Internal Medicine|January 12, 2026
High-Dose vs Standard-Dose Influenza Vaccine in Older Adults With Diabetes: A Secondary Analysis of the DANFLU-2 Randomized Clinical TrialAnne Bjerg Nielsen, Niklas Dyrby Johansen, Daniel Modin, et al.
Pageof 20

Showing results (191-200 of 199) with videos related to

Sort By:
Pageof 20
You have reached the last page of results.This site can display upto 199 results.
JAMA|August 30, 2025
Bivalent RSV Prefusion F Protein-Based Vaccine for Preventing Cardiovascular Hospitalizations in Older Adults: A Prespecified Analysis of the DAN-RSV TrialMats C Højbjerg Lassen, Niklas Dyrby Johansen, Sine H Christensen, et al.
European Journal of Preventive Cardiology|April 30, 2026
Respiratory syncytial virus vaccination and risk of respiratory and cardiorespiratory hospitalization in adults with chronic kidney disease: a prespecified analysis of the DAN-RSV trialLisa Steen Duus, Mats C H Lassen, Niklas D Johansen, et al.
European Journal of Preventive Cardiology|June 18, 2026
Effect of RSV Vaccine in Older Adults with Atrial Fibrillation: A Prespecified Analysis of the DAN-RSV TrialCaroline Espersen, Mats C H Lassen, Niklas Dyrby Johansen, et al.
JAMA Cardiology|August 30, 2025
High-Dose vs Standard-Dose Influenza Vaccine and Cardiovascular Outcomes in Older Adults: A Prespecified Secondary Analysis of the DANFLU-2 Randomized Clinical TrialNiklas Dyrby Johansen, Daniel Modin, Matthew M Loiacono, et al.
European Heart Journal|August 30, 2025
High-dose vs. standard-dose inactivated influenza vaccine and cardiovascular outcomes in persons with or without pre-existing atherosclerotic cardiovascular disease: the DANFLU-2 trialManan Pareek, Niklas Dyrby Johansen, Daniel Modin, et al.
Journal of the American College of Cardiology|November 26, 2025
High-Dose vs Standard-Dose Influenza Vaccine in Chronic Kidney Disease: The DANFLU-2 Trial Subgroup AnalysisKatja Vu Bartholdy, Niklas Dyrby Johansen, Daniel Modin, et al.
The New England Journal of Medicine|September 1, 2025
High-Dose Influenza Vaccine Effectiveness against Hospitalization in Older AdultsNiklas Dyrby Johansen, Daniel Modin, Matthew M Loiacono, et al.
Circulation. Heart Failure|August 30, 2025
High-Dose vs. Standard-Dose Influenza Vaccine in Heart Failure: A Prespecified Analysis of the DANFLU-2 TrialKristoffer Grundtvig Skaarup, Niklas Dyrby Johansen, Daniel Modin, et al.
JAMA Internal Medicine|January 12, 2026
High-Dose vs Standard-Dose Influenza Vaccine in Older Adults With Diabetes: A Secondary Analysis of the DANFLU-2 Randomized Clinical TrialAnne Bjerg Nielsen, Niklas Dyrby Johansen, Daniel Modin, et al.
Pageof 20